Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Longeveron Inc (LGVN)

Longeveron Inc (LGVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,481
  • Shares Outstanding, K 14,837
  • Annual Sales, $ 710 K
  • Annual Income, $ -21,410 K
  • EBIT $ -18 M
  • EBITDA $ -17 M
  • 60-Month Beta 0.31
  • Price/Sales 33.48
  • Price/Cash Flow N/A
  • Price/Book 0.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.36
  • Number of Estimates 3
  • High Estimate -0.33
  • Low Estimate -0.40
  • Prior Year -2.50
  • Growth Rate Est. (year over year) +85.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5900 +3.77%
on 12/20/24
2.1600 -23.61%
on 11/29/24
-0.2000 (-10.81%)
since 11/20/24
3-Month
1.5900 +3.77%
on 12/20/24
2.4843 -33.58%
on 10/28/24
-0.3900 (-19.12%)
since 09/20/24
52-Week
0.7707 +114.09%
on 06/11/24
14.8000 -88.85%
on 12/26/23
-14.5500 (-89.81%)
since 12/20/23

Most Recent Stories

More News
Longeveron Inc. CEO Wa’el Hashad to Present at Biotech Showcase 2025 on January 14

Longeveron Inc. CEO Wa’el Hashad will present at Biotech Showcase on January 14, 2025, discussing regenerative medicine developments.Quiver AI SummaryLongeveron Inc., a clinical stage biotechnology company...

LGVN : 1.6500 (+3.12%)
Longeveron to Present at Biotech Showcase 2025

LGVN : 1.6500 (+3.12%)
LGVNR : 0.0005 (-37.50%)
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

LGVN : 1.6500 (+3.12%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update

LGVN : 1.6500 (+3.12%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

LGVN : 1.6500 (+3.12%)
LGVNR : 0.0005 (-37.50%)
Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

LGVN : 1.6500 (+3.12%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)

LGVN : 1.6500 (+3.12%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

LGVN : 1.6500 (+3.12%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)

LGVN : 1.6500 (+3.12%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

LGVN : 1.6500 (+3.12%)
LGVNR : 0.0005 (-37.50%)

Business Summary

Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI.

See More

Key Turning Points

3rd Resistance Point 1.8467
2nd Resistance Point 1.7833
1st Resistance Point 1.7167
Last Price 1.6500
1st Support Level 1.5867
2nd Support Level 1.5233
3rd Support Level 1.4567

See More

52-Week High 14.8000
Fibonacci 61.8% 9.4408
Fibonacci 50% 7.7853
Fibonacci 38.2% 6.1299
Last Price 1.6500
52-Week Low 0.7707

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar